Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 220 articles:
HTML format



Single Articles


    September 2021
  1. HUANG CC, Lai CY, Tsai CH, Wang JY, et al
    Combined effects of cigarette smoking, DNA methyltransferase 3B genetic polymorphism, and DNA damage on lung cancer.
    BMC Cancer. 2021;21:1066.
    PubMed     Abstract available


  2. NIKSIC M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, et al
    The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.
    BMC Cancer. 2021;21:1048.
    PubMed     Abstract available


  3. AI X, Song Z, Jian H, Zhou Z, et al
    Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    BMC Cancer. 2021;21:1033.
    PubMed     Abstract available


  4. WU LL, Li CW, Lin WK, Qiu LH, et al
    Incidence and survival analyses for occult lung cancer between 2004 and 2015: a population-based study.
    BMC Cancer. 2021;21:1009.
    PubMed     Abstract available


  5. JAKOBSEN E, Olsen KE, Bliddal M, Hornbak M, et al
    Forecasting lung cancer incidence, mortality, and prevalence to year 2030.
    BMC Cancer. 2021;21:985.
    PubMed     Abstract available


  6. NAKANISHI K, Nakamura S, Sugiyama T, Kadomatsu Y, et al
    Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    BMC Cancer. 2021;21:983.
    PubMed     Abstract available


    August 2021
  7. GUTIERREZ L, Royuela A, Carcereny E, Lopez-Castro R, et al
    Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
    BMC Cancer. 2021;21:977.
    PubMed     Abstract available


  8. WANG C, Li J, Zhang Q, Wu J, et al
    The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    BMC Cancer. 2021;21:968.
    PubMed     Abstract available


  9. KHALIL AA, Hau E, Gebski V, Grau C, et al
    Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial.
    BMC Cancer. 2021;21:940.
    PubMed     Abstract available


  10. LIU T, Wang J, Li T, Cui P, et al
    Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles.
    BMC Cancer. 2021;21:939.
    PubMed     Abstract available


  11. ZHANG X, Cao Y, Chen L
    Construction of a prognostic signature of autophagy-related lncRNAs in non-small-cell lung cancer.
    BMC Cancer. 2021;21:921.
    PubMed     Abstract available


  12. FEIL C, Staib F, Berger MR, Stein T, et al
    Sniffer dogs can identify lung cancer patients from breath and urine samples.
    BMC Cancer. 2021;21:917.
    PubMed     Abstract available


    July 2021
  13. YU W, Ye F, Yuan X, Ma Y, et al
    A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
    BMC Cancer. 2021;21:877.
    PubMed     Abstract available


  14. WANG X, Cai J, Zeng Z, Liu A, et al
    Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:873.
    PubMed     Abstract available


  15. WU CE, Chang CF, Huang CY, Yang CT, et al
    Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:859.
    PubMed     Abstract available


  16. TANG Y, Zhang R, Li Y, Xu S, et al
    Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer.
    BMC Cancer. 2021;21:842.
    PubMed     Abstract available


  17. LUO H, Zhang Y, Qin G, Jiang B, et al
    LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer.
    BMC Cancer. 2021;21:820.
    PubMed     Abstract available


  18. HUNG A, Lee KM, Lynch JA, Li Y, et al
    Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.
    BMC Cancer. 2021;21:824.
    PubMed     Abstract available


  19. SHEN H, Deng G, Chen Q, Qian J, et al
    The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
    BMC Cancer. 2021;21:825.
    PubMed     Abstract available


  20. CHAU J, Yadav M, Liu B, Furqan M, et al
    Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
    BMC Cancer. 2021;21:808.
    PubMed     Abstract available


  21. PARK K, Kim JS, Kim JH, Kim YC, et al
    An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2021;21:802.
    PubMed     Abstract available


  22. PASCOE J, Jackson A, Gaskell C, Gaunt C, et al
    Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
    BMC Cancer. 2021;21:800.
    PubMed     Abstract available


  23. LIU T, Luo H, Zhang J, Hu X, et al
    Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer.
    BMC Cancer. 2021;21:783.
    PubMed     Abstract available


    June 2021
  24. CHRISTOPOULOS P, Bozorgmehr F, Bruckner L, Chung I, et al
    Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
    BMC Cancer. 2021;21:743.
    PubMed     Abstract available


  25. RUSMAULLY J, Tvardik N, Martin D, Billmann R, et al
    Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study).
    BMC Cancer. 2021;21:711.
    PubMed     Abstract available


  26. ZENG H, Yang Z, Li J, Wen Y, et al
    Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones.
    BMC Cancer. 2021;21:690.
    PubMed     Abstract available


  27. ZHOU H, Li J, Chen Z, Chen Y, et al
    Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.
    BMC Cancer. 2021;21:678.
    PubMed     Abstract available


  28. CHEN C, Wu Z, Wu Z, Wu C, et al
    Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.
    BMC Cancer. 2021;21:666.
    PubMed     Abstract available


    May 2021
  29. HUANG A, Xu Y, Zang X, Wu C, et al
    Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    BMC Cancer. 2021;21:634.
    PubMed     Abstract available


  30. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed     Abstract available


  31. GUO X, Ma W, Wu H, Xu Y, et al
    Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.
    BMC Cancer. 2021;21:613.
    PubMed     Abstract available


  32. WANG Q, Gao W, Gao F, Jin S, et al
    Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    BMC Cancer. 2021;21:602.
    PubMed     Abstract available


  33. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:574.
    PubMed    


  34. GO SI, Park MJ, Lee GW
    Clinical significance of the cachexia index in patients with small cell lung cancer.
    BMC Cancer. 2021;21:563.
    PubMed     Abstract available


  35. ZHU D, Ding R, Ma Y, Chen Z, et al
    Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China.
    BMC Cancer. 2021;21:557.
    PubMed     Abstract available


  36. GARGIULO P, Arenare L, Gridelli C, Morabito A, et al
    Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
    BMC Cancer. 2021;21:549.
    PubMed     Abstract available


  37. LEVITSKY A, Bernhardson BM, Henoch I, Olin M, et al
    Using patients' own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer.
    BMC Cancer. 2021;21:544.
    PubMed     Abstract available


  38. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:530.
    PubMed     Abstract available


  39. LESTER J, Escriu C, Khan S, Hudson E, et al
    Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
    BMC Cancer. 2021;21:515.
    PubMed     Abstract available


  40. ZHU L, Zou C, Zhang Z, Wang J, et al
    Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
    BMC Cancer. 2021;21:511.
    PubMed     Abstract available


  41. OKUMURA N, Soh J, Suzuki H, Nakata M, et al
    Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
    BMC Cancer. 2021;21:506.
    PubMed     Abstract available


  42. ZUO T, Lin W, Liu F, Xu J, et al
    Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.
    BMC Cancer. 2021;21:505.
    PubMed     Abstract available


  43. MA J, Li X, Zhao S, Wang J, et al
    Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2021;21:498.
    PubMed     Abstract available


  44. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available


  45. CHEN YC, Tsai MJ, Lee MH, Kuo CY, et al
    Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations.
    BMC Cancer. 2021;21:495.
    PubMed     Abstract available


  46. KRIEGSMANN K, Zgorzelski C, Muley T, Christopoulos P, et al
    Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
    BMC Cancer. 2021;21:486.
    PubMed     Abstract available


    April 2021
  47. WANG X, Zeng Z, Cai J, Xu P, et al
    Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:482.
    PubMed     Abstract available


  48. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available


  49. KAWAGUCHI Y, Hanaoka J, Ohshio Y, Okamoto K, et al
    Locoregional recurrence via mucus-mediated extension following lung resection for mucinous tumors.
    BMC Cancer. 2021;21:470.
    PubMed     Abstract available


  50. YU Y, Ren K
    Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer.
    BMC Cancer. 2021;21:457.
    PubMed     Abstract available


  51. HU J, Chen Y, Zhu X, Ma Q, et al
    Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively.
    BMC Cancer. 2021;21:445.
    PubMed     Abstract available


  52. AYERS KL, Ma M, Debussche G, Corrigan D, et al
    A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    BMC Cancer. 2021;21:441.
    PubMed     Abstract available


  53. HUANG LT, Cao R, Wang YR, Sun L, et al
    Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of ran
    BMC Cancer. 2021;21:426.
    PubMed     Abstract available


  54. ZHANG Y, Simoff MJ, Ost D, Wagner OJ, et al
    Understanding the patient journey to diagnosis of lung cancer.
    BMC Cancer. 2021;21:402.
    PubMed     Abstract available


  55. JOHNSON MK, Wu S, Pankratz DG, Fedorowicz G, et al
    Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
    BMC Cancer. 2021;21:400.
    PubMed     Abstract available


  56. STORK T, Boemans R, Hardes J, Streitburger A, et al
    Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma.
    BMC Cancer. 2021;21:375.
    PubMed     Abstract available


  57. HUANG YS, Chen JL, Chen HM, Yeh LH, et al
    Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer.
    BMC Cancer. 2021;21:348.
    PubMed     Abstract available


  58. HOSOYA K, Fujimoto D, Morimoto T, Kumagai T, et al
    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
    BMC Cancer. 2021;21:346.
    PubMed     Abstract available


  59. BADE BC, Gan G, Li F, Lu L, et al
    "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".
    BMC Cancer. 2021;21:352.
    PubMed     Abstract available


    March 2021
  60. KIM SR, Hong JH, Sung SY, Kim YH, et al
    Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study.
    BMC Cancer. 2021;21:340.
    PubMed     Abstract available


  61. VANTHOMME K, Rosskamp M, De Schutter H, Vandenheede H, et al
    Lung cancer incidence differences in migrant men in Belgium, 2004-2013: histology-specific analyses.
    BMC Cancer. 2021;21:328.
    PubMed     Abstract available


  62. KUO CS, Tung PH, Huang AC, Wang CC, et al
    A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    BMC Cancer. 2021;21:309.
    PubMed     Abstract available


  63. MIYANAGA A, Matsumoto M, Beck JA, Horikawa I, et al
    EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.
    BMC Cancer. 2021;21:310.
    PubMed     Abstract available


  64. OSELIN K, Pisarev H, Ilau K, Kiivet RA, et al
    Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer.
    BMC Cancer. 2021;21:274.
    PubMed     Abstract available


  65. SUN S, Zane A, Fulton C, Philipoom J, et al
    Statistical and bioinformatic analysis of hemimethylation patterns in non-small cell lung cancer.
    BMC Cancer. 2021;21:268.
    PubMed     Abstract available


  66. LI H, Ding L, Hong X, Chen Y, et al
    Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis.
    BMC Cancer. 2021;21:259.
    PubMed     Abstract available


  67. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available


  68. XING W, Sun H, Yan C, Zhao C, et al
    A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    BMC Cancer. 2021;21:263.
    PubMed     Abstract available


  69. ZHAO Y, Gao Y, Xu X, Zhou J, et al
    Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    BMC Cancer. 2021;21:257.
    PubMed     Abstract available


  70. TSUCHIYA T, Matsumoto K, Miyazaki T, Doi R, et al
    A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    BMC Cancer. 2021;21:249.
    PubMed     Abstract available


  71. PROVENCIO M, Terrasa J, Garrido P, Campelo RG, et al
    Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    BMC Cancer. 2021;21:230.
    PubMed     Abstract available


  72. LI Y, Zhao X, Xiao H, Yang B, et al
    APE1 may influence CD4+ naive T cells on recurrence free survival in early stage NSCLC.
    BMC Cancer. 2021;21:233.
    PubMed     Abstract available


  73. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available


  74. MINEGISHI Y, Yamaguchi O, Sugawara S, Kuyama S, et al
    A phase II study of first-line afatinib for patients aged >/=75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    BMC Cancer. 2021;21:208.
    PubMed     Abstract available


  75. ZHAI Y, Zhao B, Wang Y, Li L, et al
    Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    BMC Cancer. 2021;21:213.
    PubMed     Abstract available


    February 2021
  76. ARAUJO LH, Souza BM, Leite LR, Parma SAF, et al
    Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    BMC Cancer. 2021;21:193.
    PubMed     Abstract available


  77. CHEN J, Sun M, Zhou M, Lu R, et al
    Correction to: Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:192.
    PubMed    


  78. ZHU D, Cao D, Shen M, Lv J, et al
    Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
    BMC Cancer. 2021;21:176.
    PubMed     Abstract available


  79. ESTER M, Culos-Reed SN, Abdul-Razzak A, Daun JT, et al
    Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer.
    BMC Cancer. 2021;21:159.
    PubMed     Abstract available


  80. CHEN J, Sun M, Zhou M, Lu R, et al
    Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:158.
    PubMed     Abstract available


  81. WANG Y, Liu J, Huang C, Zeng Y, et al
    Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database.
    BMC Cancer. 2021;21:148.
    PubMed     Abstract available


  82. HE Y, Zhao F, Han Q, Zhou Y, et al
    Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors.
    BMC Cancer. 2021;21:141.
    PubMed     Abstract available


  83. PAZIK M, Michalska K, Zebrowska-Nawrocka M, Zawadzka I, et al
    Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings.
    BMC Cancer. 2021;21:130.
    PubMed     Abstract available


  84. HE X, You J, Ding H, Zhang Z, et al
    Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status.
    BMC Cancer. 2021;21:132.
    PubMed     Abstract available


  85. YANG K, Wu Y
    A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    BMC Cancer. 2021;21:128.
    PubMed     Abstract available


  86. KIDD J, Cassim S, Rolleston A, Chepulis L, et al
    Ha Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Maori communities.
    BMC Cancer. 2021;21:121.
    PubMed     Abstract available


  87. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available


    January 2021
  88. WAN Y, Yao D, Fang F, Wang Y, et al
    LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival.
    BMC Cancer. 2021;21:104.
    PubMed     Abstract available


  89. LI XS, Nie KC, Zheng ZH, Zhou RS, et al
    Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
    BMC Cancer. 2021;21:96.
    PubMed     Abstract available


  90. HAYASHI T, Shimokawa M, Matsuo K, Iihara H, et al
    Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
    BMC Cancer. 2021;21:74.
    PubMed     Abstract available


  91. ZHAO K, Wang C, Shi F, Huang Y, et al
    Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    BMC Cancer. 2021;21:66.
    PubMed     Abstract available


  92. OYA Y, Yoshida T, Asada K, Oguri T, et al
    Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    BMC Cancer. 2021;21:57.
    PubMed     Abstract available


  93. JI G, Bao T, Li Z, Tang H, et al
    Current lung cancer screening guidelines may miss high-risk population: a real-world study.
    BMC Cancer. 2021;21:50.
    PubMed     Abstract available


  94. PARK S, Lee SY, Kim D, Sim YS, et al
    Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    BMC Cancer. 2021;21:52.
    PubMed     Abstract available


  95. KU GW, Kang Y, Yu SL, Park J, et al
    LncRNA LINC00240 suppresses invasion and migration in non-small cell lung cancer by sponging miR-7-5p.
    BMC Cancer. 2021;21:44.
    PubMed     Abstract available


  96. KIM SR, Chun SH, Kim JR, Kim SY, et al
    The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    BMC Cancer. 2021;21:19.
    PubMed     Abstract available


  97. HESS LM, Han Y, Zhu YE, Bhandari NR, et al
    Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
    BMC Cancer. 2021;21:28.
    PubMed     Abstract available


  98. CORRIVEAU S, Pond GR, Tang GH, Goffin JR, et al
    A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer.
    BMC Cancer. 2021;21:14.
    PubMed     Abstract available


    December 2020
  99. LIN H, Zhang G, Zhang XC, Lian XL, et al
    Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees.
    BMC Cancer. 2020;20:1209.
    PubMed     Abstract available


  100. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
    Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
    BMC Cancer. 2020;20:1210.
    PubMed     Abstract available


  101. GONG H, Li Y, Yuan Y, Li W, et al
    EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    BMC Cancer. 2020;20:1189.
    PubMed     Abstract available


  102. TSUCHIYA T, Kamohara R, Muraoka M, Nagayasu T, et al
    A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    BMC Cancer. 2020;20:1192.
    PubMed     Abstract available


  103. ZHU X, Han J, Lan H, Lin Q, et al
    A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    BMC Cancer. 2020;20:1190.
    PubMed     Abstract available


  104. BRUECKL WM, Ficker JH, Zeitler G
    Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
    BMC Cancer. 2020;20:1185.
    PubMed     Abstract available


  105. BOUCHEZ C, Pluvy J, Soussi G, Nguenang M, et al
    Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:1186.
    PubMed     Abstract available


    November 2020
  106. XU L, Xu F, Kong H, Zhao M, et al
    Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study.
    BMC Cancer. 2020;20:1152.
    PubMed     Abstract available


  107. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available


  108. CHAI M, Shi Q
    The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.
    BMC Cancer. 2020;20:1121.
    PubMed     Abstract available


  109. WANG B, Wang DQ, Lin MS, Lu SP, et al
    Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy.
    BMC Cancer. 2020;20:1112.
    PubMed     Abstract available


  110. HIGASHIYAMA M, Miyazaki R, Yamamoto H, Anayama T, et al
    Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer.
    BMC Cancer. 2020;20:1100.
    PubMed     Abstract available


  111. XU F, Song J, Xu B, Wang J, et al
    Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer.
    BMC Cancer. 2020;20:1089.
    PubMed     Abstract available


  112. WANG H, Yin Y, Wang R, Huang J, et al
    Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia.
    BMC Cancer. 2020;20:1081.
    PubMed     Abstract available


  113. KIM MY, Shin JY, Kim JO, Son KH, et al
    Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
    BMC Cancer. 2020;20:1057.
    PubMed     Abstract available


    October 2020
  114. PARK JY, Lee YJ, Kim T, Lee CY, et al
    Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
    BMC Cancer. 2020;20:1040.
    PubMed     Abstract available


  115. HSU YC, Tsai YH, Weng HH, Hsu LS, et al
    Artificial neural networks improve LDCT lung cancer screening: a comparative validation study.
    BMC Cancer. 2020;20:1023.
    PubMed     Abstract available


  116. WANG B, Xu L, Li Q, Man S, et al
    Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    BMC Cancer. 2020;20:1021.
    PubMed     Abstract available


  117. BATRA A, Sheka D, Kong S, Cheung WY, et al
    Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer.
    BMC Cancer. 2020;20:1004.
    PubMed     Abstract available


  118. YAMAMOTO T, Niibe Y, Aoki M, Shintani T, et al
    Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
    BMC Cancer. 2020;20:997.
    PubMed     Abstract available


  119. LENG D, Yi J, Xiang M, Zhao H, et al
    Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.
    BMC Cancer. 2020;20:986.
    PubMed     Abstract available


  120. KAIRA K, Mouri A, Kato S, Yoshimura K, et al
    A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    BMC Cancer. 2020;20:961.
    PubMed     Abstract available


  121. LEI H, Wang K, Jiang T, Lu J, et al
    KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint.
    BMC Cancer. 2020;20:957.
    PubMed     Abstract available


  122. TAKEDA Y, Naka G, Yamaguchi Y, Hashimoto M, et al
    Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
    BMC Cancer. 2020;20:951.
    PubMed     Abstract available


    September 2020
  123. BILGUUN EO, Kaira K, Kawabata-Iwakawa R, Rokudai S, et al
    Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
    BMC Cancer. 2020;20:935.
    PubMed     Abstract available


  124. REZAEI M, Mostafaei S, Aghaei A, Hosseini N, et al
    The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue.
    BMC Cancer. 2020;20:916.
    PubMed     Abstract available


  125. GRIESHOBER L, Graw S, Barnett MJ, Thornquist MD, et al
    AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.
    BMC Cancer. 2020;20:905.
    PubMed     Abstract available


  126. XU X, Liu Z, Xiong W, Qiu M, et al
    Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China.
    BMC Cancer. 2020;20:903.
    PubMed     Abstract available


  127. GAO W, Liang J, Ye Y, Lu J, et al
    FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis.
    BMC Cancer. 2020;20:895.
    PubMed     Abstract available


  128. LI L, Yue HC, Han YW, Liu W, et al
    Relationship between the invasion of lymphocytes and cytokines in the tumor microenvironment and the interval after single brachytherapy hypofractionated radiotherapy and conventional fractionation radiotherapy in non-small cell lung Cancer.
    BMC Cancer. 2020;20:893.
    PubMed     Abstract available


  129. JIANG J, Adams HP, Lange M, Siemann S, et al
    Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:885.
    PubMed     Abstract available


  130. SCHLUCKEBIER L, Caetano R, Garay OU, Montenegro GT, et al
    Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
    BMC Cancer. 2020;20:875.
    PubMed     Abstract available


  131. SHINODA Y, Kobayashi E, Kobayashi H, Mori T, et al
    Prognostic factors of metastatic myxoid liposarcoma.
    BMC Cancer. 2020;20:883.
    PubMed     Abstract available


  132. PARK HY, Hwang J, Kim DH, Jeon SM, et al
    Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea.
    BMC Cancer. 2020;20:846.
    PubMed     Abstract available


  133. BAN WH, Yeo CD, Han S, Kang HS, et al
    Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer.
    BMC Cancer. 2020;20:848.
    PubMed     Abstract available


  134. WANG J, Liu Z, Pang Q, Zhang T, et al
    Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    BMC Cancer. 2020;20:837.
    PubMed     Abstract available


  135. ARRIETA O, Catalan R, Guzman-Vazquez S, Barron F, et al
    Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    BMC Cancer. 2020;20:829.
    PubMed     Abstract available


    August 2020
  136. SAURABH K, Shah PP, Doll MA, Siskind LJ, et al
    UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
    BMC Cancer. 2020;20:824.
    PubMed     Abstract available


  137. NAGHIBZADEH-TAHAMI A, Marzban M, Yazdi-Feyzabadi V, Dabiri S, et al
    Is opium use associated with an increased risk of lung cancer? A case-control study.
    BMC Cancer. 2020;20:807.
    PubMed     Abstract available


  138. BU X, Liu J, Wei L, Wang X, et al
    Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis.
    BMC Cancer. 2020;20:811.
    PubMed     Abstract available


  139. DUAN H, Liang L, Xie S, Wang C, et al
    The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    BMC Cancer. 2020;20:809.
    PubMed     Abstract available


  140. BOZORGMEHR F, Chung I, Christopoulos P, Krisam J, et al
    Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    BMC Cancer. 2020;20:806.
    PubMed     Abstract available


  141. LI J, Zheng Q, Zhao X, Zhao J, et al
    Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis.
    BMC Cancer. 2020;20:793.
    PubMed     Abstract available


  142. LIANG J, Li J, Li Z, Meng T, et al
    Differentiating the lung lesions using Intravoxel incoherent motion diffusion-weighted imaging: a meta-analysis.
    BMC Cancer. 2020;20:799.
    PubMed     Abstract available


  143. TAKANASHI Y, Funai K, Sato S, Kawase A, et al
    Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
    BMC Cancer. 2020;20:800.
    PubMed     Abstract available


  144. RADES D, Werner EM, Glatzel E, Eggert MC, et al
    Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis.
    BMC Cancer. 2020;20:785.
    PubMed     Abstract available


  145. JIANG H, Xu S, Chen C
    A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    BMC Cancer. 2020;20:782.
    PubMed     Abstract available


  146. LORENZO-LUACES P, Sanchez L, Saavedra D, Crombet T, et al
    Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    BMC Cancer. 2020;20:772.
    PubMed     Abstract available


  147. ZHONG L, Xie L, Yang Z, Li L, et al
    Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    BMC Cancer. 2020;20:766.
    PubMed     Abstract available


  148. DICKHOFF C, Senan S, Schneiders FL, Veltman J, et al
    Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    BMC Cancer. 2020;20:764.
    PubMed     Abstract available


  149. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available


  150. RAMELOW J, Brooks CD, Gao L, Almiman AA, et al
    The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
    BMC Cancer. 2020;20:738.
    PubMed     Abstract available


  151. WU X, Zhang X, Tao L, Chen P, et al
    Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC).
    BMC Cancer. 2020;20:719.
    PubMed     Abstract available


    July 2020
  152. JIA M, Yu S, Yu J, Li Y, et al
    Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.
    BMC Cancer. 2020;20:705.
    PubMed     Abstract available


  153. CHEN Y, Hu J, Bu F, Zhang H, et al
    Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:707.
    PubMed     Abstract available


  154. OUYANG W, Yu J, Zhou Y, Hu J, et al
    Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:699.
    PubMed     Abstract available


  155. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available


  156. JIA B, Zheng Q, Wang J, Sun H, et al
    A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database.
    BMC Cancer. 2020;20:666.
    PubMed     Abstract available


  157. AYE PS, Tin Tin S, McKeage MJ, Khwaounjoo P, et al
    Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    BMC Cancer. 2020;20:658.
    PubMed     Abstract available


  158. SUN Y, Wu M, Zhou M, Luo X, et al
    Management of medically inoperable and tyrosine kinase inhibitor-naive early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    BMC Cancer. 2020;20:646.
    PubMed     Abstract available


  159. PAN ST, Zhou J, Yang F, Zhou SF, et al
    Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells.
    BMC Cancer. 2020;20:634.
    PubMed     Abstract available


  160. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available


    June 2020
  161. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available


  162. MA F, Xie Y, Lei Y, Kuang Z, et al
    The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.
    BMC Cancer. 2020;20:580.
    PubMed     Abstract available


  163. KANG DH, Jung SS, Yeo MK, Lee DH, et al
    Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    BMC Cancer. 2020;20:571.
    PubMed     Abstract available


  164. TENG X, Wei L, Han L, Min D, et al
    Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer.
    BMC Cancer. 2020;20:562.
    PubMed     Abstract available


  165. LAKE M, Shusted CS, Juon HS, McIntire RK, et al
    Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up.
    BMC Cancer. 2020;20:561.
    PubMed     Abstract available


  166. LIEVERSE RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, et al
    Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
    BMC Cancer. 2020;20:557.
    PubMed     Abstract available


  167. HUANG T, Sun H, Luo X, Zhang X, et al
    Correlation study between flash dual source CT perfusion imaging and regional lymph node metastasis of non-small cell lung cancer.
    BMC Cancer. 2020;20:547.
    PubMed     Abstract available


  168. LIU Q, Huang Y, Chen H, Liu Y, et al
    The development and validation of a radiomic nomogram for the preoperative prediction of lung adenocarcinoma.
    BMC Cancer. 2020;20:533.
    PubMed     Abstract available


  169. LIU Y, Zhu Y, Bai L, Chen F, et al
    Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma.
    BMC Cancer. 2020;20:520.
    PubMed     Abstract available


  170. KOSHIMUNE S, Kosaka M, Mizuno N, Yamamoto H, et al
    Prognostic value of OCT4A and SPP1C transcript variant co-expression in early-stage lung adenocarcinoma.
    BMC Cancer. 2020;20:521.
    PubMed     Abstract available


  171. CHEN J, Xia J, Huang J, Xu R, et al
    Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.
    BMC Cancer. 2020;20:510.
    PubMed     Abstract available


  172. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available


    May 2020
  173. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available


  174. EL YACOUBI H, Sow ML, Kettani F, Gamra L, et al
    Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
    BMC Cancer. 2020;20:479.
    PubMed     Abstract available


  175. SOLARI JIG, Filippi-Chiela E, Pilar ES, Nunes V, et al
    Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    BMC Cancer. 2020;20:474.
    PubMed     Abstract available


  176. HOWLETT J, Benzenine E, Cottenet J, Foucher P, et al
    Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study.
    BMC Cancer. 2020;20:461.
    PubMed     Abstract available


  177. KESSEL KA, Grosser RCE, Kraus KM, Hoffmann H, et al
    Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO).
    BMC Cancer. 2020;20:442.
    PubMed     Abstract available


  178. DE MOL M, Visser S, Aerts J, Lodder P, et al
    The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
    BMC Cancer. 2020;20:431.
    PubMed     Abstract available


  179. WU X, Yu W, Petersen RH, Sheng H, et al
    A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.
    BMC Cancer. 2020;20:429.
    PubMed     Abstract available


  180. HU L, Zhang P, Mei Q, Sun W, et al
    Podoplanin is a useful prognostic marker and indicates better differentiation in lung squamous cell cancer patients? A systematic review and meta-analysis.
    BMC Cancer. 2020;20:424.
    PubMed     Abstract available


  181. WAGENER-RYCZEK S, Heydt C, Suptitz J, Michels S, et al
    Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:408.
    PubMed     Abstract available


  182. KALINAUSKAITE GG, Tinhofer II, Kufeld MM, Kluge AA, et al
    Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    BMC Cancer. 2020;20:404.
    PubMed     Abstract available


  183. BERKOVIC P, Gulyban A, Defraene G, Swenen L, et al
    Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.
    BMC Cancer. 2020;20:402.
    PubMed     Abstract available


  184. YOON SH, Kim HS, Kim RN, Jung SY, et al
    NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis.
    BMC Cancer. 2020;20:375.
    PubMed     Abstract available


  185. KEPPENS C, Dequeker EMC, Rouleau E, 't Hart N, et al
    Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples.
    BMC Cancer. 2020;20:366.
    PubMed     Abstract available


  186. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available


    April 2020
  187. CHIANG AC, Fernandes AW, Pavilack M, Wu JW, et al
    EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:356.
    PubMed     Abstract available


  188. KITAGAWA Y, Osumi H, Shinozaki E, Ota Y, et al
    Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective stud
    BMC Cancer. 2020;20:358.
    PubMed     Abstract available


  189. ZOU Y, Xu L, Tang Q, You Q, et al
    Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    BMC Cancer. 2020;20:344.
    PubMed     Abstract available


  190. HAZELL SZ, Mai N, Fu W, Hu C, et al
    Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact.
    BMC Cancer. 2020;20:334.
    PubMed     Abstract available


  191. QIN K, Hou H, Liang Y, Zhang X, et al
    Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2020;20:328.
    PubMed     Abstract available


  192. JIN X, Guan Y, Zhang Z, Wang H, et al
    Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.
    BMC Cancer. 2020;20:329.
    PubMed     Abstract available


  193. YAO W, Wang L, Huang H, Li X, et al
    All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
    BMC Cancer. 2020;20:315.
    PubMed     Abstract available


  194. SHEILL G, Guinan E, O'Neill L, Normand C, et al
    Preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or oesophagus (PRE-HIIT): protocol for a randomized controlled trial.
    BMC Cancer. 2020;20:321.
    PubMed     Abstract available


  195. SHAH N, Liu Z, Tallman RM, Mohammad A, et al
    Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
    BMC Cancer. 2020;20:292.
    PubMed     Abstract available


  196. STEEGHS EMP, Kroeze LI, Tops BBJ, van Kempen LC, et al
    Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    BMC Cancer. 2020;20:291.
    PubMed     Abstract available


  197. SANO K, Nakadate K, Hanada K
    Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
    BMC Cancer. 2020;20:279.
    PubMed     Abstract available


  198. BI N, Liu L, Liang J, Wu S, et al
    Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
    BMC Cancer. 2020;20:278.
    PubMed     Abstract available


  199. HANSEN RN, Zhang Y, Seal B, Ryan K, et al
    Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
    BMC Cancer. 2020;20:276.
    PubMed     Abstract available


  200. DELGADO-GARCIA M, Weynand B, Gomez-Izquierdo L, Hernandez MJ, et al
    Clinical performance evaluation of the Idylla EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
    BMC Cancer. 2020;20:275.
    PubMed     Abstract available


    March 2020
  201. HARDTSTOCK F, Myers D, Li T, Cizova D, et al
    Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
    BMC Cancer. 2020;20:260.
    PubMed     Abstract available


  202. XU N, Liu F, Wu S, Ye M, et al
    CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
    BMC Cancer. 2020;20:262.
    PubMed     Abstract available


  203. ZHAO J, Xiang C, Zhao R, Guo P, et al
    Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    BMC Cancer. 2020;20:248.
    PubMed     Abstract available


  204. SIEBENHUNER AR, Guller U, Warschkow R
    Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
    BMC Cancer. 2020;20:246.
    PubMed     Abstract available


  205. MOSS C, Haire A, Cahill F, Enting D, et al
    Guy's cancer cohort - real world evidence for cancer pathways.
    BMC Cancer. 2020;20:187.
    PubMed     Abstract available


  206. YANG F, Hu M, Chang S, Huang J, et al
    Alteration in the sensitivity to crizotinib by Na(+)/H(+) exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers.
    BMC Cancer. 2020;20:202.
    PubMed     Abstract available


  207. DIMOU A, Barron G, Merrick DT, Kolfenbach J, et al
    Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
    BMC Cancer. 2020;20:177.
    PubMed     Abstract available


    February 2020
  208. DREVINSKAITE M, Patasius A, Kevlicius L, Mickys U, et al
    Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
    BMC Cancer. 2020;20:162.
    PubMed     Abstract available


  209. CAI Y, Wu H, Shi X, Dong Y, et al
    Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
    BMC Cancer. 2020;20:148.
    PubMed     Abstract available


  210. TOKUDOME N, Koh Y, Akamatsu H, Fujimoto D, et al
    Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
    BMC Cancer. 2020;20:103.
    PubMed     Abstract available


  211. KOGO M, Fujimoto D, Hosoya K, Nagata K, et al
    Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
    BMC Cancer. 2020;20:104.
    PubMed     Abstract available


  212. MORITA M, Tamiya M, Fujimoto D, Tamiya A, et al
    Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
    BMC Cancer. 2020;20:93.
    PubMed     Abstract available


    January 2020
  213. RUIZ-CORDERO R, Ma J, Khanna A, Lyons G, et al
    Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    BMC Cancer. 2020;20:83.
    PubMed     Abstract available


  214. LI X, Zhang W, Yu Y, Zhang G, et al
    CT features and quantitative analysis of subsolid nodule lung adenocarcinoma for pathological classification prediction.
    BMC Cancer. 2020;20:60.
    PubMed     Abstract available


  215. FOWLER H, Belot A, Ellis L, Maringe C, et al
    Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers.
    BMC Cancer. 2020;20:2.
    PubMed     Abstract available


  216. LV Z, Lei T
    Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
    BMC Cancer. 2020;20:56.
    PubMed     Abstract available


  217. GUISIER F, Piton N, Bellefleur M, Delberghe N, et al
    Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
    BMC Cancer. 2020;20:14.
    PubMed     Abstract available


    December 2019
  218. GUAN J, Luo Z, Xiao Z, Xie Y, et al
    Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
    BMC Cancer. 2019;19:1188.
    PubMed     Abstract available


    November 2019
  219. TENG X, Teng X
    First report of pulmonary sclerosing pneomucytoma with malignant transformation in both cuboidal surface cells and stromal round cells: a case report.
    BMC Cancer. 2019;19:1154.
    PubMed     Abstract available


  220. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: